PMID- 28434112
OWN - NLM
STAT- MEDLINE
DCOM- 20180418
LR  - 20181113
IS  - 1573-7373 (Electronic)
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 133
IP  - 2
DP  - 2017 Jun
TI  - Dendritic cell based vaccination strategy: an evolving paradigm.
PG  - 223-235
LID - 10.1007/s11060-017-2446-4 [doi]
AB  - Malignant gliomas (MG), tumors of glial origin, are the most commonly diagnosed 
      primary intracranial malignancies in adults. Currently available treatments have 
      provided only modest improvements in overall survival and remain limited by 
      inevitable local recurrence, necessitating exploration of novel therapies. Among 
      approaches being investigated, one of the leading contenders is immunotherapy, 
      which aims to modulate immune pathways to stimulate the selective destruction of 
      malignant cells. Dendritic cells (DCs) are potent initiators of adaptive immune 
      responses and therefore crucial players in the development and success of 
      immunotherapy. Clinical trials of various DC-based vaccinations have demonstrated 
      the induction of anti-tumor immune responses and prolonged survival in the 
      setting of many cancers. In this review, we summarize current literature 
      regarding DCs and their role in the tumor microenvironment, their application and 
      current clinical use in immunotherapy, current challenges limiting their efficacy 
      in anti-cancer therapy, and future avenues for developing successful anti-tumor 
      DC-based vaccines.
FAU - Filley, Anna C
AU  - Filley AC
AD  - Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, 
      IN, USA.
FAU - Dey, Mahua
AU  - Dey M
AD  - Department of Neurosurgery, Indiana University School of Medicine, Indianapolis, 
      IN, USA. mdey@iu.edu.
AD  - Indiana University Purdue University Indianapolis (IUPUI), 320 W 15th Street, 
      Neuroscience Building NB400A, Indianapolis, IN, 46202, USA. mdey@iu.edu.
LA  - eng
GR  - K08 NS092895/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170422
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/immunology/*therapy
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/*physiology
MH  - Glioma/immunology/*therapy
MH  - Humans
PMC - PMC5532060
MID - NIHMS870628
OTO - NOTNLM
OT  - Dendritic cell based vaccine
OT  - Glioblastoma
OT  - Immunotherapy
OT  - Malignant glioma
COIS- Conflict of interest Authors declare no conflict of interest.
EDAT- 2017/04/24 06:00
MHDA- 2018/04/19 06:00
PMCR- 2018/06/01
CRDT- 2017/04/24 06:00
PHST- 2017/01/23 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2017/04/24 06:00 [pubmed]
PHST- 2018/04/19 06:00 [medline]
PHST- 2017/04/24 06:00 [entrez]
PHST- 2018/06/01 00:00 [pmc-release]
AID - 10.1007/s11060-017-2446-4 [pii]
AID - 10.1007/s11060-017-2446-4 [doi]
PST - ppublish
SO  - J Neurooncol. 2017 Jun;133(2):223-235. doi: 10.1007/s11060-017-2446-4. Epub 2017 
      Apr 22.